OncoMatch/Clinical Trials/NCT07076550
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Is NCT07076550 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [225Ac]Ac-A9-3408 for melanoma metastatic.
Treatment: [225Ac]Ac-A9-3408 — The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. The main questions this study aims to answer are: * What are the side effects of this investigational drug? * What is the highest dose of this investigational drug that can be given safely? Participants will: * Take the investigational drug once every 6 weeks, for up to 6 times in total * Visit a doctor's office on a regular basis for checkups and tests
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: standard of care therapy
disease progression on prior standard of care therapy
Cannot have received: radioactive nuclides
Exception: radioactive imaging tracers
Previous treatment with radioactive nuclides except radioactive imaging tracers
Lab requirements
Blood counts
Adequate baseline organ function within 14 days of first dose of investigational product
Kidney function
Adequate baseline organ function within 14 days of first dose of investigational product
Liver function
Adequate baseline organ function within 14 days of first dose of investigational product
Adequate baseline organ function within 14 days of first dose of investigational product
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify